1. Home
  2. EXAS vs PCVX Comparison

EXAS vs PCVX Comparison

Compare EXAS & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EXAS
  • PCVX
  • Stock Information
  • Founded
  • EXAS 1995
  • PCVX 2013
  • Country
  • EXAS United States
  • PCVX United States
  • Employees
  • EXAS N/A
  • PCVX N/A
  • Industry
  • EXAS Medical Specialities
  • PCVX Biotechnology: Pharmaceutical Preparations
  • Sector
  • EXAS Health Care
  • PCVX Health Care
  • Exchange
  • EXAS Nasdaq
  • PCVX Nasdaq
  • Market Cap
  • EXAS 10.2B
  • PCVX 4.0B
  • IPO Year
  • EXAS N/A
  • PCVX 2020
  • Fundamental
  • Price
  • EXAS $52.38
  • PCVX $30.89
  • Analyst Decision
  • EXAS Strong Buy
  • PCVX Strong Buy
  • Analyst Count
  • EXAS 22
  • PCVX 8
  • Target Price
  • EXAS $67.38
  • PCVX $114.17
  • AVG Volume (30 Days)
  • EXAS 2.8M
  • PCVX 1.6M
  • Earning Date
  • EXAS 11-04-2025
  • PCVX 11-04-2025
  • Dividend Yield
  • EXAS N/A
  • PCVX N/A
  • EPS Growth
  • EXAS N/A
  • PCVX N/A
  • EPS
  • EXAS N/A
  • PCVX N/A
  • Revenue
  • EXAS $2,939,949,000.00
  • PCVX N/A
  • Revenue This Year
  • EXAS $16.68
  • PCVX N/A
  • Revenue Next Year
  • EXAS $12.08
  • PCVX N/A
  • P/E Ratio
  • EXAS N/A
  • PCVX N/A
  • Revenue Growth
  • EXAS 12.55
  • PCVX N/A
  • 52 Week Low
  • EXAS $38.81
  • PCVX $27.66
  • 52 Week High
  • EXAS $72.83
  • PCVX $121.06
  • Technical
  • Relative Strength Index (RSI)
  • EXAS 56.95
  • PCVX 43.22
  • Support Level
  • EXAS $46.30
  • PCVX $31.47
  • Resistance Level
  • EXAS $56.52
  • PCVX $33.32
  • Average True Range (ATR)
  • EXAS 1.67
  • PCVX 1.34
  • MACD
  • EXAS 0.26
  • PCVX -0.00
  • Stochastic Oscillator
  • EXAS 59.49
  • PCVX 16.87

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

About PCVX Vaxcyte Inc.

Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.

Share on Social Networks: